/Incyte%20Corp_%20phone%20and%20logo-by%20T_Schneider%20via%20Shutterstock.jpg)
Delaware-based Incyte Corporation (INCY) focuses on the discovery, development, and commercialization of therapeutics for hematology, oncology, and inflammation & autoimmunity conditions. Valued at nearly $14 billion by market cap, Incyte’s expertise in medicinal chemistry and biology has enabled it to create a diversified portfolio of marketed products and clinical candidates.
The biopharma major is expected to announce its fourth-quarter results on Tuesday, Feb. 11. Ahead of the event, analysts expect Incyte to report a profit of $1.34 per share, up by a staggering 63.4% from $0.82 per share reported in the year-ago quarter. However, the company has missed Wall Street’s bottom-line estimates in each of the past four quarters.